Core Insights - Strata Critical Medical, Inc. reported a strong Q4 2025 with organic growth of 35%, exceeding expectations and leading to a full-year performance that surpassed guidance on all fronts [1][24] - The company is raising its revenue and adjusted EBITDA guidance for 2026 due to strong volumes and new customer acquisitions [1][29] Financial Performance - Full-year 2025 revenue reached $197.1 million and adjusted EBITDA was $14.1 million, both exceeding the high end of guidance [24] - Q4 2025 revenue was $66.8 million, driven by logistics growth of 35.3% to $49.2 million compared to $36.4 million in the prior year [24][27] - Clinical revenue in Q4 2025 was $17.6 million, significantly up from $2.8 million in Q3 2025, reflecting the impact of the Keystone acquisition [24][25] Growth Strategy - Continued acquisitions of smaller businesses are a key part of the company's strategy to accelerate growth and expand geographically [5][15] - The company expects to maintain an average annualized adjusted EBITDA growth rate of at least 30% over the coming years, driven by successful execution of its M&A strategy [15][16] Regulatory Environment - Recent regulatory changes are seen as beneficial for Strata Critical Medical, particularly in incentivizing the pursuit of medically complex organs [8][10] - The company is well-positioned with a customer base that is over-indexed to larger, more sophisticated transplant centers, which are favored under new regulations [10][11] Operational Highlights - The company ended the year with a fleet of approximately 30 dedicated or owned aircraft and plans to add two new owned aircraft to support new geographies in 2026 [12][13] - Logistics gross profit increased by 39.5% to $10.6 million in Q4 2025, driven by strong revenue growth and improved gross margins [27] Future Outlook - The company raised its 2026 revenue guidance range to $260–$275 million from $255–$270 million previously, and adjusted EBITDA guidance to $29–$33 million from $28–$32 million [29] - Despite a modest sequential revenue decline expected in Q1 2026, the company anticipates a sequential improvement in revenue and margin in the second quarter and the latter half of the year [31]

Q3 2025 Performance - Product revenue reached $87.7 million, representing a 33.1% year-over-year growth but an 8.8% decrease compared to the previous quarter[3] - Total revenue for Q3 2025 was $143.8 million, a 32.2% increase year-over-year but an 8.6% decrease quarter-over-quarter[4] - Service revenue amounted to $56.1 million, showing a 30.9% year-over-year growth but an 8.4% decrease from the previous quarter[5] - Net income for Q3 2025 was $24.3 million, a significant increase of $20.1 million year-over-year but a decrease of $10.6 million quarter-over-quarter[5] - Total cash reached $466.2 million, an increase of $65.6 million quarter-over-quarter[5] Revenue Breakdown by Organ - Liver revenue was $107.94 million, a 40.8% increase year-over-year but a 7.0% decrease quarter-over-quarter[11, 16] - Heart revenue was $30.589 million, a 13.6% increase year-over-year and a 14.2% decrease quarter-over-quarter[11, 16] - Lung revenue was $4.11 million, a 5.2% increase year-over-year and a 10.2% decrease quarter-over-quarter[11, 16] Service Revenue Details - Clinical service revenue decreased by 8.7% quarter-over-quarter but increased by 29.0% year-over-year[14] - Logistics revenue decreased by 8.9% quarter-over-quarter but increased by 35.2% year-over-year[14] - Flight school revenue increased by 15.7% quarter-over-quarter but decreased by 5.7% year-over-year[14] Financial Metrics - Gross margin for Q3 2025 was 58.8%, a 2.9 percentage point increase year-over-year but a 2.6 percentage point decrease quarter-over-quarter[4] - Operating margin for Q3 2025 was 16.2%, a 12.6 percentage point increase year-over-year[4] Updated 2025 Revenue Guidance - The company updated its total revenue guidance for 2025 to a range of $595 million to $605 million, projecting a 36% growth at the midpoint of the range[20]